Development and demonstration of Cas13‑based antiviral CRISPR strategy

Published in: Cell (2020)

What This Study Showed

This paper demonstrated an innovative CRISPR‑Cas13‑based antiviral approach called PAC‑MAN (Prophylactic Antiviral CRISPR in huMAN cells) that uses an RNA‑targeting CRISPR system to directly degrade viral RNA from SARS‑CoV‑2 and other RNA viruses in human cells.

Key technical features include:

Use of Cas13d, an RNA‑targeting CRISPR nuclease, programmed with guide RNAs (crRNAs) to recognize essential regions of the viral RNA genome.
Efficient degradation of SARS‑CoV‑2 RNA in cultured human respiratory cells, reducing viral replication when directed against conserved viral sequences.
The strategy was prophylactic — designed to be active before or at early stages of infection — highlighting potential use for broad‑spectrum antiviral interventions.

Why This Paper Is Important

Novel Antiviral CRISPR Application

Unlike traditional genome editing that alters DNA, Cas13 targets RNA directly, making it uniquely suited to combating RNA viruses (like SARS‑CoV‑2) by cleaving viral genomes or transcripts inside infected cells.

Rapid Pandemic Relevance

Published early in the COVID‑19 pandemic, this work provided one of the first proof‑of‑concept demonstrations that programmable CRISPR systems could be repurposed as antiviral tools against emerging pathogens, not just for diagnostics.

Foundation for Future Antiviral Biotech Platforms

PAC‑MAN and similar Cas13 approaches opened avenues for:

Broad‑spectrum antiviral design against multiple RNA viruses
RNA‑targeting therapeutics complementing vaccines and small molecules
New diagnostics that can both detect and disable viral RNA

Summary

This Cell paper was a biotechnology breakthrough showing how programmable RNA‑targeting CRISPR tools (PAC‑MAN) can be engineered to directly destroy viral RNA inside human cells, offering a new drug‑like antiviral strategy — especially relevant during the early phase of the COVID‑19 pandemic.

BioTech IP Review